Stay updated on COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma

Sign up to get notified when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.
Latest website image capture
Clouds background image

Latest updates to the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    7 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.3%
    Check dated 2024-06-13T22:31:56.000Z thumbnail image
  6. Check
    14 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the medical and healthcare-related publications or documentation.
    Difference
    0.3%
    Check dated 2024-06-06T14:42:44.000Z thumbnail image
  7. Check
    29 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating an update in the number of versions of the study record for the clinical trial 'Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD)'. This change reflects the addition of a new version of the study record, which may include updated information or results.
    Difference
    0.3%
    Check dated 2024-05-22T21:36:45.000Z thumbnail image
  8. Check
    51 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:31:38.000Z thumbnail image

Stay in the know with updates to COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma

Enter your email address, and we'll notify you when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.